Incorporating Recently Approved FLT3 Inhibitors as Maintenance Therapy for Patients With a History of FLT3-Mutated AML

Intended Audience: Hematologists/oncologists and their teams of NPs, PAs, nurses, and pharmacists caring for patients with AML

Managing patients with FLT3-mutated AML can be challenging. Ensure you are up to date with the latest evidence and guideline recommendations for maintenance monotherapy with recently approved FLT3 inhibitors for patients with FLT3-mutated AML.

Customized learning pathways based on the speed and accuracy of your answers will provide you with real-time feedback and resources targeted to your level of knowledge. This curated education covers outcomes from clinical trials, recent guideline updates, and insights on maintenance monotherapy recommendations and adverse event management for FLT3 inhibitors. Upon completion, you will receive a personalized downloadable resource with all of the information presented to you during the activity.

• Assess recent clinical trial data and guideline recommendations for maintenance monotherapy following consolidation or transplantation for patients with FLT3-mutated AML
  
  
• Employ appropriate evidence-based strategies for early recognition, mitigation, and management of adverse effects associated with FLT3 inhibitors

• 0.25 CME/CE for Physicians (ACCME)
• 0.25 CME/CE for Physician Assistants (AAPA)
• 0.25 CH/CE for Nurse Practitioners (AANP)
• 0.25 CPE for Pharmacists (ACPE + NABP)
• 0.25 CNE for Nurses (ANCC)

This activity is provided by PRIME Education. There is no fee to participate. This activity is supported by an educational grant from Daiichi Sankyo, Inc